Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
Rhea-AI Summary
Seer, Inc. (Nasdaq: SEER), a prominent life sciences company focusing on proteomics, has announced its plans to release third quarter 2024 financial results on Wednesday, November 6, 2024. The company will host a conference call and webcast to discuss the results, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors and interested parties can access the live audio webcast through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SEER declined 0.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact:
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio